Notice of Intent to Publish a Funding Opportunity Announcement for Investigation of the Transmission of Kaposi Sarcoma-Associated Herpesvirus (KSHV) (R01 Clinical Trial Optional)
Notice Number:

Key Dates

Release Date:
September 02, 2020
Estimated Publication Date of Funding Opportunity Announcement:
October 01, 2020
First Estimated Application Due Date:
December 14, 2020
Earliest Estimated Award Date:
June 15, 2021
Earliest Estimated Start Date:
June 15, 2021
Related Announcements


Issued by

National Cancer Institute (NCI)


The National Cancer Institute (NCI) intends to promote a reissuance of an initiative by publishing a Funding Opportunity Announcement (FOA) to solicit applications to advance our understanding of the modes of transmission of Kaposi sarcoma-associated herpesvirus (KSHV), also called human herpesvirus-8 (HHV-8); the biology of the initial steps of infection; and risk factors for infection to inform efforts to prevent KSHV transmission and thus prevent Kaposi sarcoma (KS), KSHV-associated multicentric Castleman disease (MCD), primary effusion lymphoma (PEL), and other KSHV-induced diseases in populations living with HIV or at high risk of developing HIV.

This Notice is being provided to allow potential applicants time to develop responsive projects and meaningful collaborations.

The FOA is expected to use the R01 mechanism with approximately 4-6 awards to be made. Clinical trial is optional.

The FOA is expected to be published in October 2020 with an expected application due date in December 2020.

Details of the planned FOA is being provided below.

Research Initiative Details

This Notice encourages investigators with expertise and insights into the area of Kaposi sarcoma-associated herpesvirus (KSHV) to begin to consider applying for this reissued FOA.

Among the areas of research encouraged in this initiative are the epidemiology and biology of KSHV transmission; the biologic factors that protect against early steps in KSHV infection; the biological research of the immune responses to KSHV infection; biological and epidemiological research examining the mechanisms that underlie modes of KSHV transmission; epidemiological research to better define the behavioral, environmental, or genetic risk factors for KSHV transmission; as well as research designed to improve the translation of existing knowledge of strategies for the prevention of KSHV transmission. In addition, collaborative investigations combining expertise in serological or DNA based assays for KSHV, KSHV infection, immune responses to KSHV and KSHV transmission will be encouraged and these investigators should also begin considering applying for this FOA.

The presentation of this initiative to the NCI Board of Scientific Advisors (BSA) can be accessed at this link (at time frame 4:13):

The link to the previous RFA can be accessed here:

Funding Information
Estimated Total Funding

Up to $3,000,000 in both fiscal year (FY) 2021 and 2022

Expected Number of Awards

Approximately 4-6 R01 awards each fiscal year

Estimated Award Ceiling

$500,000 Direct Costs per year

Primary CFDA Numbers

93.396, 93.399

Anticipated Eligible Organizations
Indian/Native American Tribal Government (Other than Federally Recognized)
Public/State Controlled Institution of Higher Education
Private Institution of Higher Education
Nonprofit with 501(c)(3) IRS Status (Other than Institution of Higher Education)
Small Business
For-Profit Organization (Other than Small Business)
State Government
County governments
Independent school districts
Public housing authorities/Indian housing authorities
U.S. Territory or Possession
Regional Organization
Eligible Agencies of the Federal Government
Indian/Native American Tribal Government (Federally Recognized)

Applications are not being solicited at this time. 


Please direct all inquiries to:

Rebecca Liddell Huppi, Ph.D.

National Cancer Institute (NCI)



Weekly TOC for this Announcement
NIH Funding Opportunities and Notices